Portfolio Design Labs LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Portfolio Design Labs LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 19.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,799 shares of the company’s stock after buying an additional 454 shares during the quarter. Portfolio Design Labs LLC’s holdings in Zoetis were worth $456,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. Wealthcare Capital Partners LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at $308,000. Stonebridge Financial Group LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at $170,000. Summit Trail Advisors LLC grew its stake in shares of Zoetis by 46.9% in the fourth quarter. Summit Trail Advisors LLC now owns 9,269 shares of the company’s stock valued at $1,510,000 after buying an additional 2,961 shares in the last quarter. Finally, Arlington Trust Co LLC grew its stake in shares of Zoetis by 55.6% in the fourth quarter. Arlington Trust Co LLC now owns 1,327 shares of the company’s stock valued at $216,000 after buying an additional 474 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Zoetis Trading Down 0.2 %

NYSE:ZTS opened at $173.99 on Thursday. The stock has a 50-day simple moving average of $169.11 and a 200-day simple moving average of $179.11. The stock has a market cap of $78.50 billion, a P/E ratio of 32.70, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. Zoetis’s dividend payout ratio is currently 37.59%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ZTS. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley lowered their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Finally, Piper Sandler lowered their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $214.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.